

Electronic Supplementary Information for *Chemical Communications*

A Highly Efficient Access to Enantiopure Tetrahydropyridines: Dual-organocatalyst-promoted Asymmetric Cascade Reaction

Hua Lin, Yu Tan, Wen-Jie Liu, Zhi-Cheng Zhang, Xing-Wen Sun* and Guo-Qiang Lin*

Department of Chemistry, Fudan University, 220 Handan Road, Shanghai, 200433, P.R.China

Email: sunxingwen@fudan.edu.cn; lingq@sioc.ac.cn


Contents

- I. General experimental methods. (P2)
- II. General procedure for the synthesis of tetrahydropyridine derivates 5a-5l. (P2)
- III. General procedure for the synthesis of tetrahydropyridine derivates 5m-5o. (P2~P3)
- IV. Characterization data and copies of HPLC spectra of tetrahydropyridine derivates 5a-5o. (P3~P17)
- V. Procedure for the synthesis of pyridine derivates 10. (P18)
- VI. Characterization data of compound 10. (P18)
- VII. X-ray crystal structure of compound 5j. (P19)
- VIII. X-ray crystal structure of compound 10. (P20)
- IX. Copies of NMR spectra. (P21~P52)

General experimental methods:


NMR spectra were all recorded on a ECA (400 MHz) spectrometer. Chemical shifts are reported in δ ppm referenced to an internal SiMe₄ standard for ¹H NMR and chloroform-d (δ 77.0) for ¹³C NMR. Optical rotations were measured in CHCl₃ on a Rudolph research analytical, Auto pol ® LV, automatic polarimeter. HPLC was performed on an Agilent 1100 series instrument or a Jasco uv-2075 plus intelligent uv/vis detector by using Daicel Chiracel AS-H column or Phenomenex Lux 5u Amylose-2 column. Flash column chromatography was performed using silica gel (300–400 mesh). Analytical thin-layer chromatography was performed using glass plates pre-coated with 0.25 mm 300–400 mesh silica gel impregnated with a fluorescent indicator (254 nm). Thin layer chromatography plates were visualized by exposure to ultraviolet light. Commercial reagents and solvents were used as received. Dichloromethane was fractionally distilled.

General procedure for the synthesis of tetrahydropyridine derivates **5a–5l**:




A solution of nitroalkene **2** (0.25 mmol), *p*-nitrophenol (5 mol%) and catalyst **7a** (5 mol%) in CH₂Cl₂ (0.25 mL) was added with aldehyade **1** (1.25 mmol). The result mixture was stirred at room temperature until all the nitroalkene was consumed, then cooled to 0 °C, added with catalyst **8b** (20 mol%), PMPNH₂ (1.25 mmol) and 4Å MS (100 mg). The mixture was kept at 0 °C for 48 hours before diluted with CH₂Cl₂, filtered through a short pad of celite. The filtrate was concentrated and purified on silica gel to afford the desired product.

General procedure for the synthesis of tetrahydropyridine derivates **5m–5o**:



A solution of nitroalkene **2** (0.25 mmol), *p*-nitrophenol (10 mol%) and catalyst **7a** (10 mol%) in CH₂Cl₂ (0.25 mL) was added with aldehyade **1** (0.3 mmol). The result mixture was stirred at room temperature until all the nitroalkene was consumed, then cooled to 0 °C, added with aldehyde **3** (1 mmol), catalyst **8b** (20 mol%), PMPNH₂ (1 mmol) and 4Å MS

(100 mg). The mixture was kept at 0 °C for 48 hours before diluted with CH₂Cl₂, filtered through a short pad of celite. The filtrate was concentrated and purified on silica gel to afford the desired product.



(2S,3R,4R)-2-ethyl-1-(4-methoxyphenyl)-5-methyl-3-nitro-4-phenyl-1,2,3,4-tetrahydropyridine (5a)



Purified by FC (PE:EtOAc = 30:1). Orange solid. The ee was determined by chiral HPLC using a Phenomenex Lux 5u Amylose-2 column (hexane/i-PrOH = 90/10); flow rate 1 mL/min; λ = 230 nm; $\tau_{\text{major}} = 12.0$ min, $\tau_{\text{minor}} = 11.0$ min, 99% ee.


$$[\alpha]_D^{15} = +381.7 \text{ (c} = 1.0, \text{CH}_3\text{Cl})$$

¹H-NMR (CDCl₃, 400 MHz): δ 7.21-7.31 (m, 5H), 6.98 (d, *J*=8.4 Hz, 2H), 6.86 (d, *J*=8.8 Hz, 2H), 6.35 (s, 1H), 5.09 (t, *J*=4.8 Hz, 1H), 4.04-4.09 (m, 1H), 3.77 (s, 3H), 3.76 (d, *J*=6.4 Hz, 1H), 1.71-1.76 (m, 2H), 1.63 (s, 3H), 1.07 (t, *J*=7.6, Hz, 3H)

¹³C-NMR (CDCl₃, 100 MHz): δ 154.7, 140.5, 136.3, 129.3, 128.5, 128.2, 127.7, 119.9, 114.5, 105.6, 87.0, 57.9, 55.6, 44.3, 24.3, 18.6, 9.7

HRMS (APCI) *m/z* calcd for C₂₁H₂₅N₂O₃ [M+H]⁺ 353.1865, found: 353.1864








(2S,3R,4R)-2-ethyl-1-(4-methoxyphenyl)-5-methyl-3-nitro-4-(p-tolyl)-1,2,3,4-tetrahydropyridine (5b)

Purified by FC (PE:EtOAc = 30:1). Orange solid. The ee was determined by chiral HPLC using a Phenomenex Lux 5u Amylose-2 column (hexane/*i*-PrOH = 90/10); flow rate 1 mL/min; λ = 230 nm; $\tau_{\text{major}} = 10.8$ min, $\tau_{\text{minor}} = 10.1$ min, 97% ee. $[\alpha]_D^{15} = +338.7$ ($c = 1.0$, CH₃Cl).

¹H-NMR (CDCl₃, 400 MHz): δ 7.10-7.12 (m, 4H), 6.99 (d, J =8.8 Hz, 2H), 6.87 (d, J =8.8 Hz, 2H), 6.35 (s, 1H), 5.09 (t, J =4.8 Hz, 1H), 4.06-4.10 (m, 1H), 3.78 (s, 3H), 3.76 (d, J =6.4 Hz, 1H), 2.32 (s, 3H), 1.67-1.78 (m, 2H), 1.63 (s, 3H), 1.07 (t, J =7.6 Hz, 3H) **¹³C-NMR (CDCl₃, 100 MHz):** δ 154.7, 140.5, 137.3, 133.1, 129.2, 129.2, 128.0, 119.9, 114.5, 105.8, 87.0, 57.8, 55.5, 44.0, 24.3, 21.1, 18.6, 9.7

HRMS (APCI) *m/z* calcd for C₂₂H₂₇N₂O₃ [M+H]⁺ 367.2022, found: 367.2023







(2S,3R,4R)-2-ethyl-1,4-bis(4-methoxyphenyl)-5-methyl-3-nitro-1,2,3,4-tetrahydropyridine (5c)


Purified by FC (PE:EtOAc = 30:1). Orange solid. The ee was determined by chiral HPLC using a Phenomenex Lux 5u Amylose-2 column (hexane/*i*-PrOH = 90/10); flow rate 1 mL/min; λ = 230 nm; $\tau_{\text{major}} = 25.4$ min, $\tau_{\text{minor}} = 23.9$ min, >99% ee. $[\alpha]_D^{15} = +275.2$ (c = 1.0, CH₃Cl).

¹H-NMR (CDCl₃, 400 MHz): δ 7.15 (d, *J*=8.0 Hz, 2H), 6.98 (d, *J*=8.4 Hz, 2H), 6.86 (d, *J*=8.4 Hz, 4H), 6.33 (s, 1H), 5.07 (t, *J*=4.8 Hz, 1H), 4.04–4.07 (m, 1H), 3.78 (s, 6H), 3.75 (d, *J*=6.8 Hz, 1H), 1.69–1.76 (m, 2H), 1.63 (s, 3H), 1.07 (t, *J*=7.6 Hz, 3H)

¹³C-NMR (CDCl₃, 100 MHz): δ 159.2, 154.8, 140.6, 130.5, 130.2, 128.2, 120.1, 114.6, 114.0, 106.1, 87.2, 57.9, 55.7, 55.3, 43.7, 29.8, 24.4, 18.7, 9.8

HRMS (APCI) *m/z* calcd for C₂₂H₂₇N₂O₄ [M+H]⁺ 383.1971, found: 383.1972






(2*S*,3*R*,4*R*)-4-(4-chlorophenyl)-2-ethyl-1-(4-methoxyphenyl)-5-methyl-3-nitro-1,2,3,4-tetrahydropyridine (5d)

Purified by FC (PE:EtOAc = 30:1). Orange solid. The ee was determined by chiral HPLC using a Daicel Chiracel AS-H column (hexane/*i*-PrOH = 90/10); flow rate 1 mL/min; λ = 230 nm; $\tau_{\text{major}} = 16.8$ min, $\tau_{\text{minor}} = 8.4$ min, 98% ee.
 $[\alpha]_D^{15} = +290.8$ ($c = 1.0$, CH₃Cl).


¹H-NMR (CDCl₃, 400 MHz): δ 7.30 (d, *J*=8.4 Hz, 2H), 7.17 (d, *J*=8.0 Hz, 2H), 6.98 (d, *J*=8.8 Hz, 2H), 6.86 (d, *J*=8.8 Hz, 2H), 6.35 (s, 1H), 5.07 (t, *J*=4.8 Hz, 1H), 4.04-4.07 (m, 1H), 3.78 (s, 3H), 3.75 (d, *J*=5.6 Hz, 1H), 1.69-1.76 (m, 2H), 1.61 (s, 3H), 1.07 (t, *J*=7.6 Hz, 3H). **¹³C-NMR (CDCl₃, 100 MHz):** δ 154.8, 140.3, 134.9, 133.6, 130.7, 128.7, 128.5, 119.9, 114.5, 105.0, 86.8, 57.9, 55.6, 43.7, 24.2, 18.5, 9.7

HRMS (APCI) *m/z* calcd for C₂₁H₂₄ClN₂O₃ [M+H]⁺ 387.1475, found: 387.1482




Results

Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		8.357	4054.716	104914.844	1.1627
2		16.798	118725.109	8918574.000	98.8373
Total			122779.825	9023488.844	100.0000



Results

Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		8.390	194554.719	5541365.500	50.2083
2		17.090	71155.078	5495385.500	49.7917
Total			265709.797	11036751.000	100.0000




(2S,3R,4R)-4-(4-bromophenyl)-2-ethyl-1-(4-methoxyphenyl)-5-methyl-3-nitro-1,2,3,4-tetrahydropyridine (5e)

Purified by FC (PE:EA=30:1). Orange solid. The ee was determined by chiral HPLC using a Daicel Chiracel AS-H column (hexane/*i*-PrOH = 99/1); flow rate 0.5 mL/min; λ = 230 nm; τ_{major} = 28.7 min, τ_{minor} = 26.5 min, 96% ee.
 $[\alpha]_D^{15} = +129.1$ ($c = 0.5$, CH₃Cl).


¹H-NMR (CDCl₃, 400 MHz): δ 7.30 (d, J =7.6 Hz, 2H), 7.17 (d, J =7.6 Hz, 2H), 6.97 (d, J =8.0 Hz, 2H), 6.86 (d, J =8.4 Hz, 2H), 6.35 (s, 1H), 5.07 (t, J = 4.8 Hz, 1H), 4.04-4.07 (m, 1H), 3.78 (s, 3H), 3.75 (d, J =6.4 Hz, 1H), 1.65-1.78 (m, 2H), 1.61 (s, 3H), 1.07 (t, J = 7.6 Hz, 3H) **¹³C-NMR (CDCl₃, 100 MHz):** δ 154.8, 140.3, 134.9, 133.6, 130.7, 128.7, 128.5, 120.0, 114.5, 105.0, 86.8, 57.8, 55.6, 43.7, 29.7, 24.2, 18.5, 9.7

HRMS (APCI) *m/z* calcd for C₂₁H₂₄BrN₂O₃ [M+H]⁺ 431.0970, found: 431.0972




Results

Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		26.507	2899.361	190897.063	2.1828
2		28.707	85969.539	8554718.000	97.8172
Total			88868.900	8745615.063	100.0000



Results

Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		26.927	72188.094	5521151.000	48.5967
2		29.347	58765.578	5840011.500	51.4033
Total			130953.672	11361162.500	100.0000




(2S,3R,4R)-4-(2-chlorophenyl)-2-ethyl-1-(4-methoxyphenyl)-5-methyl-3-nitro-1,2,3,4-tetrahydropyridine (5f)

Purified by FC (PE:EA=30:1). Orange solid. The ee was determined by chiral HPLC using a Daicel Chiracel AS-H column (hexane/i-PrOH = 90/10); flow rate 1 mL/min; $\lambda = 230$ nm; $\tau_{\text{major}} = 16.7$ min, $\tau_{\text{minor}} = 8.3$ min, 97% ee.


$[\alpha]_D^{15} = +590.7$ ($c = 1.0$, CH_3Cl).

$^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.49 (d, $J=7.6$ Hz, 1H), 7.18 (d, $J=8.8$ Hz, 2H), 7.06 (d, $J=6.8$ Hz, 1H), 6.84 (d, $J=8.4$ Hz, 2H), 6.76 (d, $J=8.0$ Hz, 2H), 6.33 (s, 1H), 5.28 (d, $J=4.8$ Hz, 1H), 4.19 (d, $J=5.2$ Hz, 1H), 4.02-4.07 (m, 1H), 3.68 (s, 3H), 1.81-1.89 (m, 1H), 1.69-1.76 (m, 1H), 1.58 (s, 3H), 1.13 (t, $J=7.6$ Hz, 3H). **$^{13}\text{C-NMR}$ (CDCl_3 , 100 MHz):** δ 154.1, 140.7, 134.6, 132.7, 131.6, 129.2, 127.5, 127.3, 125.7, 118.0, 114.5, 106.0, 83.7, 60.4, 55.6, 41.9, 25.3, 18.4, 10.7, HRMS (APCI) m/z calcd for $\text{C}_{21}\text{H}_{24}\text{ClN}_2\text{O}_3$ [$\text{M}+\text{H}]^+$ 387.1475, found: 387.1477




Results

Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		8.313	2729.280	78489.398	1.4934
2		16.678	68672.453	5177363.500	98.5066
Total			71401.733	5255852.898	100.0000



Results

Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		8.415	81662.250	2288705.000	51.0535
2		17.315	29417.785	2194249.500	48.9465
Total			111080.035	4482954.500	100.0000






(2S,3R,4R)-2-ethyl-4-(furan-2-yl)-1-(4-methoxyphenyl)-5-methyl-3-nitro-1,2,3,4-tetrahydropyridine (5g)

Purified by FC (PE:EtOAc = 30:1). Orange solid. The ee was determined by chiral HPLC using a Phenomenex Lux 5u Amylose-2 column (hexane/*i*-PrOH = 90/10); flow rate 1 mL/min; λ = 230 nm; $\tau_{\text{major}} = 11.7$ min, $\tau_{\text{minor}} = 10.9$ min, 96% ee.
 $[\alpha]_D^{15} = +145.1$ ($c = 0.5$, CH₃Cl).

¹H-NMR (CDCl₃, 400 MHz): δ 7.36 (s, 1H), 6.97 (d, $J=8.8$ Hz, 2H), 6.85 (d, $J=8.8$ Hz, 2H), 6.34 (s, 1H), 6.24 (d, $J=10.4$ Hz, 2H), 5.11 (t, $J=4.8$ Hz, 1H), 4.10-4.14 (m, 1H), 3.95 (d, $J=5.2$ Hz, 1H), 3.77 (s, 3H), 1.71-1.78 (m, 2H), 1.68 (s, 3H), 1.06 (t, $J=7.6$ Hz, 3H) **¹³C-NMR (CDCl₃, 100 MHz):** δ 155.0, 150.4, 142.2, 140.3, 127.9, 120.5, 114.5, 110.6, 109.4, 103.6, 84.5, 58.3, 55.5, 38.4, 24.2, 18.3, 9.5

HRMS (APCI) *m/z* calcd for C₁₉H₂₃N₂O₄ [M+H]⁺ 343.1658, found: 343.1668








(2S,3R,4R)-2-ethyl-1-(4-methoxyphenyl)-5-methyl-3-nitro-4-(thiophen-2-yl)-1,2,3,4-tetrahydropyridine (5h)

Purified by FC (PE:EtOAc = 30:1). Orange solid. The ee was determined by chiral HPLC using a Phenomenex Lux 5u Amylose-2 column (hexane/*i*-PrOH = 90/10); flow rate 1 mL/min; λ = 230 nm; $\tau_{\text{major}} = 11.0$ min, $\tau_{\text{minor}} = 10.1$ min, 94% ee.
 $[\alpha]_D^{15} = +159.3$ ($c = 1.0$, CH₃Cl).

¹H-NMR (CDCl₃, 400 MHz): δ 7.24 (d, $J=8.0$ Hz, 2H), 7.03 (d, $J=7.6$ Hz, 2H), 6.88-6.96 (m, 2H), 6.86 (d, $J=8.0$ Hz, 2H), 6.20 (s, 1H), 5.02 (t, $J=4.8$ Hz, 1H), 4.14 (d, $J=5.2$ Hz, 1H), 4.11 (d, $J=4.8$ Hz, 1H), 3.78 (s, 3H), 1.68 (s, 3H), 1.60-1.68 (m, 2H), 0.99 (t, $J=6.8$ Hz, 3H) **¹³C-NMR (CDCl₃, 100 MHz):** δ 155.5, 140.0, 139.9, 129.1, 127.5, 127.0, 125.3, 122.0, 114.5, 105.1, 86.4, 56.3, 55.5, 40.7, 23.2, 18.5, 8.8

HRMS (ESI) *m/z* calcd for C₁₉H₂₃N₂O₃S [M+H]⁺ 359.1429, found: 359.1416







(2*S*,3*R*,4*R*)-5-ethyl-1-(4-methoxyphenyl)-3-nitro-4-phenyl-2-propyl-1,2,3,4-tetrahydropyridine (5i)


Purified by FC (PE:EtOAc = 100:1). Orange solid. The ee was determined by chiral HPLC using a Phenomenex Lux 5u Amylose-2 column (hexane/i-PrOH = 90/10); flow rate 1 mL/min; λ = 230 nm; $\tau_{\text{major}} = 9.5$ min, $\tau_{\text{minor}} = 8.9$ min, 96% ee.

$[\alpha]_D^{15} = +345.9$ ($c = 1.0$, CH₃Cl).

¹H-NMR (CDCl₃, 400 MHz): δ 7.21-7.31 (m, 5H), 6.97 (d, $J=8.0$ Hz, 2H), 6.85 (d, $J=8.4$ Hz, 2H), 6.37 (s, 1H), 5.06 (t, $J=4.8$ Hz, 1H), 4.11-4.16 (m, 1H), 3.87 (d, $J=5.2$ Hz, 1H), 3.77 (s, 3H), 1.95-2.07 (m, 2H), 1.60-1.71 (m, 2H), 1.52-1.60 (m, 2H), 0.92-0.98 (m, 6H). **¹³C-NMR (CDCl₃, 100 MHz):** δ 154.7, 140.6, 136.4, 129.4, 128.4, 127.7, 126.9, 119.7, 114.5, 111.7, 87.4, 57.0, 55.6, 42.5, 33.6, 25.5, 18.6, 14.1, 13.2

HRMS (APCI) *m/z* calcd for C₂₃H₂₉N₂O₃ [M+H]⁺ 381.2178, found: 381.2185








(2S,3R,4R)-2-isobutyl-5-isopropyl-1-(4-methoxyphenyl)-3-nitro-4-phenyl-1,2,3,4-tetrahydropyridine (5j)

Purified by FC (PE:EtOAc = 200:1). Orange solid. The ee was determined by chiral HPLC using a Phenomenex Lux 5u Amylose-2 column (hexane/i-PrOH = 90/10); flow rate 1 mL/min; λ = 230 nm; $\tau_{\text{major}} = 7.4$ min, $\tau_{\text{minor}} = 6.4$ min, 96% ee.
 $[\alpha]_D^{15} = +415.5$ ($c = 1.0$, CH₃Cl).

¹H-NMR (CDCl₃, 400 MHz): δ 7.21-7.30 (m, 5H), 6.93 (d, $J=7.6$ Hz, 2H), 6.85 (d, $J=8.0$ Hz, 2H), 6.38 (s, 1H), 5.00-5.04 (m, 1H), 4.19-4.22 (m, 1H), 3.89 (d, $J=5.6$ Hz, 1H), 3.76 (s, 3H), 2.23-2.26 (m, 1H), 1.81-1.84 (m, 1H), 1.67-1.73 (m, 1H), 1.56-1.59 (m, 1H), 0.89-1.17 (m, 12H) **¹³C-NMR (CDCl₃, 100 MHz):** δ 154.3, 141.0, 136.6, 129.4, 128.5, 127.6, 124.8, 118.6, 116.6, 114.6, 87.7, 56.4, 55.6, 41.8, 40.9, 28.8, 24.5, 23.3, 22.5, 20.0

HRMS (APCI) *m/z* calcd for C₂₅H₃₃N₂O₃ [M+H]⁺ 409.2491, found: 409.2489







(2S,3R,4R)-5-benzyl-1-(4-methoxyphenyl)-3-nitro-2-phenethyl-4-phenyl-1,2,3,4-tetrahydropyridine (5k)


Purified by FC (PE:EtOAc = 20:1). Orange solid. The ee was determined by chiral HPLC using a Phenomenex Lux 5u Amylose-2 column (hexane/i-PrOH = 90/10); flow rate 1 mL/min; λ = 230 nm; $\tau_{\text{major}} = 18.4$ min, $\tau_{\text{minor}} = 15.7$ min, 94% ee.
 $[\alpha]_D^{15} = +173.7$ ($c = 1.0$, CH₃Cl).

¹H-NMR (CDCl₃, 400 MHz): δ 7.05-7.28 (m, 13H), 6.82-6.95 (m, 6H), 6.58 (s, 1H), 4.95-5.00 (m, 1H), 4.15-4.22 (m, 1H), 3.75 (s, 3H), 3.47 (d, $J=5.6$ Hz, 1H), 3.38 (d, $J=14.4$ Hz, 1H), 3.22 (d, $J=14.4$ Hz, 1H), 2.76 (t, $J=7.2$ Hz, 2H), 1.81-1.95 (m, 2H)

¹³C-NMR (CDCl₃, 100 MHz): δ 154.8, 140.7, 140.2, 140.0, 135.6, 129.6, 128.6, 128.5, 128.4, 128.2, 127.7, 126.3, 126.1, 119.3, 114.6, 110.9, 87.1, 57.3, 55.6, 41.6, 39.1, 33.6, 31.8

HRMS (APCI) m/z calcd for C₃₃H₃₃N₂O₃ [M+H]⁺ 505.2491, found: 505.2494







(2*S*,3*R*,4*R*)-5-heptyl-1-(4-methoxyphenyl)-3-nitro-2-octyl-4-phenyl-1,2,3,4-tetrahydropyridine (5l)


Purified by FC (PE:EtOAc = 20:1). Orange solid. The ee was determined by chiral HPLC using a Phenomenex Lux 5U Amylose-2 column (hexane/*i*-PrOH = 90/10); flow rate 1

mL/min; λ = 230 nm; τ_{major} = 5.9 min, τ_{minor} = 5.5 min, 96% ee. $[\alpha]_D^{15} = +263.4$ ($c = 1.0$, CH₃Cl).

¹H-NMR (CDCl₃, 400 MHz): δ 7.24-7.33 (m, 5H), 6.99 (d, $J=8.4$ Hz, 2H), 6.88 (d, $J=8.8$ Hz, 2H), 6.40 (s, 1H), 5.07 (t, $J=1.2$ Hz, 1H), 4.13-4.19 (m, 1H), 3.86 (d, $J=5.6$ Hz, 1H), 3.79 (s, 3H), 1.95-2.09 (m, 2H), 1.62-1.82 (m, 2H), 1.45-1.57 (m, 2H), 1.15-1.42 (m, 20H), 0.86-0.94 (m, 6H) **¹³C-NMR (CDCl₃, 100 MHz):** δ 154.7, 140.7, 136.5, 129.5, 128.6, 127.8, 127.7, 119.7, 114.7, 110.2, 87.5, 57.4, 55.7, 42.6, 32.5, 31.9, 31.7, 29.7, 29.5, 29.3, 29.2, 28.3, 25.4, 22.7, 14.2

HRMS (APCI) *m/z* calcd for C₃₃H₄₉N₂O₃ [M+H]⁺ 521.3743, found: 521.3737





(2S,3R,4R)-5-benzyl-2-ethyl-1-(4-methoxyphenyl)-3-nitro-4-phenyl-1,2,3,4-tetrahydropyridine (5m)

Purified by FC (PE:EtOAc = 30:1). Orange solid. The ee was determined by chiral HPLC using a Phenomenex Lux 5u Amylose-2 column (hexane/i-PrOH = 90/10); flow rate 1 mL/min; λ = 230 nm; $\tau_{\text{major}} = 13.9$ min, $\tau_{\text{minor}} = 12.2$ min, 90% ee.
 $[\alpha]_D^{15} = +281.8$ ($c = 1.17$, CH₃Cl).



¹H-NMR (CDCl₃, 400 MHz): δ 7.16-7.30 (m, 8H), 7.00 (d, J =8.0 Hz, 2H), 6.93 (d, J =6.4 Hz, 2H), 6.87 (d, J =8.0 Hz, 2H), 6.52 (s, 1H), 4.99 (t, J =4.8 Hz, 1H), 4.03-4.09 (m, 1H), 3.78 (s, 3H), 3.54 (d, J =5.2 Hz, 1H), 3.37 (d, J =14.4 Hz, 1H),


3.22 (d, J =14.4 Hz, 1H), 1.56-1.68 (m, 2H), 1.03 (t, J =6.8Hz, 3H)

¹³C-NMR (CDCl₃, 100 MHz): δ 154.8, 140.3, 140.0,

135.9, 129.6, 128.8, 128.5, 128.2, 127.8, 126.1, 119.8, 114.5, 110.0, 86.9, 58.3, 55.6, 41.8, 39.1, 24.6, 9.8

HRMS (ESI) m/z calcd for C₂₇H₂₉N₂O₃ [M+H]⁺ 428.2178, found: 429.2177







(2S,3R,4R)-1-(4-methoxyphenyl)-3-nitro-4-phenyl-2,5-dipropyl-1,2,3,4-tetrahydropyridine (5n)


Purified by FC (PE:EtOAc = 30:1). Orange solid. The ee was determined by chiral HPLC using a Phenomenex Lux 5u Amylose-2 column (hexane/i-PrOH = 90/10); flow rate 1 mL/min; $\lambda = 230$ nm; $\tau_{\text{major}} = 9.1$ min, $\tau_{\text{minor}} = 8.3$ min, 94% ee.

$[\alpha]_D^{15} = +375.1$ ($c = 1.0$, CH₃Cl).

¹H-NMR (CDCl₃, 400 MHz): δ 7.24-7.33 (m, 5H), 6.97 (d, $J=8.0$ Hz, 2H), 6.85 (d, $J=8.0$ Hz, 2H), 6.38 (s, 1H), 5.05 (t, $J=4.8$ Hz, 1H), 4.11-4.19 (m, 1H), 3.83 (d, $J=6.4$ Hz, 1H), 3.76 (s, 3H), 2.02-2.10 (m, 1H), 1.88-1.95 (m, 1H), 1.60-1.78 (m, 2H), 1.48-1.58 (m, 2H), 1.17-1.41 (m, 2H), 0.98 (t, $J=6.4$ Hz, 3H), 0.82 (t, $J=6.4$ Hz, 3H) **¹³C-NMR (CDCl₃, 100 MHz):** δ 154.5, 140.5, 136.3, 129.4, 128.4, 127.6, 127.6, 119.5, 114.5, 109.7, 87.3, 57.1, 55.5, 42.3, 34.5, 33.8, 21.3, 18.7, 14.1, 13.6

HRMS (ESI) m/z calcd for C₂₄H₃₁N₂O₃ [M+H]⁺ 395.2335, found: 395.2320







(2S,3R,4R)-2-butyl-5-ethyl-1-(4-methoxyphenyl)-3-nitro-4-phenyl-1,2,3,4-tetrahydropyridine (5o)


Purified by FC (PE:EtOAc = 50:1). Orange solid. The ee was determined by chiral HPLC using a Phenomenex Lux 5u Amylose-2 column (hexane/i-PrOH = 90/10); flow rate 1 mL/min; λ = 230 nm; $\tau_{\text{major}} = 8.3$ min, $\tau_{\text{minor}} = 7.7$ min, 93% ee.
 $[\alpha]_D^{15} = +318.3$ ($c = 1.0$, CH₃Cl).

¹H-NMR (CDCl₃, 400 MHz): δ 7.22-7.30 (m, 5H), 6.97 (d, $J=7.6$ Hz, 2H), 6.86 (d, $J=7.6$ Hz, 2H), 6.37 (s, 1H), 5.08 (t, $J=4.8$ Hz, 1H), 4.11-4.17 (m, 1H), 3.87 (d, $J=4.8$ Hz, 1H), 3.77 (s, 3H), 1.91-2.10 (m, 2H), 1.56-1.77 (m, 2H), 1.28-1.51 (m, 4H), 0.89-0.96 (m, 6H) **¹³C-NMR (CDCl₃, 100 MHz):** δ 154.6, 140.5, 136.4, 129.3, 128.4, 127.7, 126.9, 119.7, 114.5, 111.7, 87.3, 57.0, 55.5, 42.5, 31.0, 27.3, 25.5, 22.7, 13.9, 13.2


HRMS (ESI) m/z calcd for C₂₄H₃₁N₂O₃ [M+H]⁺ 395.2335, found: 395.2331



Procedure for the synthesis of pyridine derivates 10:



A solution of **5a** (0.1 mmol) in CH_2Cl_2 (0.5 mL) was cooled to 0 °C, then added with benzoquinone (0.5 mmol) and $\text{BF}_3 \cdot \text{OEt}_2$ (0.15 mmol). The result mixture was stirred at 0 °C for 5 hours before quenched with NaHCO_3 (sat. aq.), extracted with CH_2Cl_2 , dried over Na_2SO_4 , filtered and concentrated, purified on silica gel to afford the desired product.



(2S,3R,4R,4aS,9aR)-2-ethyl-1-(4-methoxyphenyl)-4a-methyl-3-nitro-4-phenyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-b]pyridin-6-ol (10)



Purified by FC (PE:EtOAc = 8:1). Orange solid. $[\alpha]_D^{25} = -247.98$ ($c = 1.0, \text{CH}_3\text{Cl}$).

$^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.31-7.33 (m, 7H), 6.95 (d, $J=9.2$ Hz, 2H), 6.82 (d, $J=2.4$ Hz, 1H), 6.89-6.75 (m, 2H), 4.77 (s, 1H), 4.61-4.65 (m, 1H), 4.50-4.55 (m, 1H), 3.84 (s, 3H), 3.78 (d, $J=8.8$ Hz, 1H), 1.41-1.55 (m, 1H), 1.26 (s, 3H), 0.56 (t, $J=7.8$ Hz, 3H) **$^{13}\text{C-NMR}$ (CDCl_3 , 100 MHz):** δ 155.1, 151.4, 150.1, 140.5, 134.3, 130.6, 128.8, 128.3, 121.0, 116.4, 114.8, 110.1, 109.7, 100.7, 87.8, 55.6, 54.8, 53.0, 49.1, 29.7, 27.7, 25.7, 9.4

HRMS (EI) m/z calcd for $\text{C}_{27}\text{H}_{28}\text{N}_2\text{O}_5$ $[\text{M}]^+$ 460.1998, found: 460.2000.


X-ray crystal structure of compound 5j

The absolute configurations of all synthetic tetrahydropyridines **5a-o** were assigned based on the known stereochemistry of Michael addition in the first step together with the determination of relative configuration of the tetrahydropyridine product **5j** through X-ray crystallography.





X-ray crystal structure of compound 10


The absolute configurations of two new formed stereocenters in compound **10** were determined based on its crystal structure.





10






















5c




















5g








32





5g






































5n

